Interactive Obesity Treatment for Pregnancy
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to test the effectiveness of GROWell, a mobile health tool designed to help pregnant women who are overweight or obese manage weight gain during pregnancy and lose weight postpartum. The tool provides personalized goals, daily support messages, self-monitoring, and skills training, all delivered via text messages. Participants will either use GROWell or receive general pregnancy-related information for comparison. Women who are 10-16 weeks pregnant, have a BMI between 25 and 40, and receive care at UC Davis clinics may be a good fit. As an unphased study, this trial offers participants the chance to contribute to innovative research that could improve health outcomes for pregnant women.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your healthcare provider.
What prior data suggests that the GROWell mHealth tool is safe for use during pregnancy?
Research has shown that the GROWell tool helps pregnant women manage their weight gain. This mobile health tool uses text messages to support personal goals, provide daily encouragement, enable self-monitoring, and offer skills training.
Regarding safety, GROWell poses no physical risk as it is a digital tool and does not involve drugs or medical procedures. Instead, it aids users in making lifestyle and behavior changes, which are generally safe. Studies on similar mobile health tools have shown they are well-tolerated, with few or no side effects reported.
In summary, GROWell offers a digital method for managing weight during pregnancy. It supports healthy habits, making it a low-risk option for those concerned about safety.12345Why are researchers excited about this trial?
Researchers are excited about the GROWell approach because it offers a personalized and interactive way to manage obesity during pregnancy, unlike traditional methods that often focus on standard diet and exercise advice. GROWell uses Self-regulation Theory to empower expectant mothers through personalized goal setting, daily support messages, behavior self-monitoring with feedback, and skills training, all delivered via text messages. This innovative use of technology and tailored interaction could make it easier for pregnant women to maintain healthy weight goals, potentially leading to better health outcomes for both the mother and baby.
What evidence suggests that the GROWell mHealth tool is effective for managing pregnancy weight gain?
Research has shown that managing weight during pregnancy can reduce health risks for both mothers and babies. One study of over 16,000 women with obesity found that maintaining weight change between losing 2.2 pounds and gaining 8.8 pounds significantly lowered the risk of major health problems in newborns. In this trial, participants may receive the GROWell tool, designed to help manage weight gain during pregnancy by focusing on personal goals, daily support, self-monitoring, and skills training. Early studies suggest that these strategies may help pregnant and postpartum women achieve healthier weight outcomes. While specific results for GROWell are still under investigation, it aims to provide a dedicated tool for weight control during and after pregnancy. Another group in this trial will receive Attention Support Control, which offers information specific to pregnancy, labor, delivery, and early infancy, but not to diet, to reduce potential placebo effects.12467
Who Is on the Research Team?
Leigh Ann Simmons, PhD
Principal Investigator
University of California, Davis
Are You a Good Fit for This Trial?
The GROWell trial is for pregnant women who are overweight or obese with a BMI between 25 and 40. Participants should be in their first or early second trimester, not have given birth in the last year, and plan to deliver at UC Davis Medical Center. They must also be able to use text messaging.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive daily text messages with tailored education, problem-solving skills, and support to aid their personalized dietary goals during pregnancy
Postpartum Treatment
Participants continue to receive support and monitoring for postpartum weight loss through text messages
Follow-up
Participants are monitored for postpartum weight retention and adherence to goals
What Are the Treatments Tested in This Trial?
Interventions
- Attention Support Control
- GROWell
Trial Overview
This study tests the GROWell program, an mHealth tool designed to help manage weight during pregnancy and after giving birth. It will compare the effectiveness of this tool against standard attention support control in promoting healthy weight gain and postpartum weight loss.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Active Control
With Self-regulation Theory as the framework, the Interactive Obesity Treatment Approach Adapted for Pregnancy/Postpartum includes four components: (1) personalized goal setting, (2) daily support and educational messages, (3) self-monitoring of behavior with tailored feedback, and (4) skills training. Each component aligns with the self- regulatory processes shown in previous studies to be necessary for behavior change. All interactions with participants are via text using a cell phone.
The attention control will be delivered using text messaging to reduce the potential placebo effect that interacting with our mHealth system may have on pregnancy weight gain and postpartum weight loss. Information will be provided to control group participants that is specific to pregnancy, labor, delivery, and early infancy, but not to diet. Texts are specific to the participant's partner, pregnancy, employment, and breastfeeding plans/status.
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of California, Davis
Lead Sponsor
Pattern Health
Collaborator
National Institute of Nursing Research (NINR)
Collaborator
Duke University
Collaborator
Published Research Related to This Trial
Citations
Goals for Reaching Optimal Wellness (GROWell): A clinical ...
Outcomes associated with GWG and pregnancy are expected in late 2023, while outcomes on postpartum weight retention GROWell adherence are expected in late 2024.
Interactive Obesity Treatment for Pregnancy
In a study of 16,808 women with obesity, a gestational weight change of -1 to +4 kg was found to significantly reduce the risk of major neonatal morbidity ...
Goals for Reaching Optimal Wellness (GROWell) - PubMed
Outcomes associated with GWG and pregnancy are expected in late 2023, while outcomes on postpartum weight retention GROWell adherence are expected in late 2024.
The effect of methods used in the management of maternal ...
The study revealed that methods used in the treatment of maternal obesity may reduce some negative maternal and newborn outcomes.
(PDF) Goals for Reaching Optimal Wellness (GROWell)
Results Intervention and usual‐care participants did not significantly differ in 12‐month mean postpartum weight change (1.1 vs. 1.6 kg, p = 0.5; difference − ...
A clinical trial protocol of a digital dietary intervention ...
Goals for Reaching Optimal Wellness (GROWell): A clinical trial protocol of a digital dietary intervention for pregnant and postpartum people with prenatal ...
7.
clinicaltrial.be
clinicaltrial.be/en/details/54757?per_page=20&only_recruiting=0&only_eligible=0&only_active=0Goals for Reaching Optimal Wellness: GROWell - Clinical T...
With Self-regulation Theory as the framework, the Interactive Obesity Treatment Approach Adapted for Pregnancy/Postpartum includes four ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.